Emerging class of therapeutics represents a coming wave for developers and manufacturers

Jan 22, 2014

After years of research, development and testing, a new class of drugs is emerging on the market with two frontrunners acting as harbingers of what's to come. The cover story in Chemical & Engineering News, ACS' weekly newsmagazine, explores the potential of these antibody-drug conjugates (ADCs) and the challenges in developing and manufacturing them.

Ann M. Thayer, senior correspondent at C&EN, explains that ADCs are essentially molecular missiles. They are made up of a toxic payload (a drug) attached to an antibody that specifically seeks out sick cells, such as tumor cells. They don't release their lethal cargo until they reach their target. The advantages of this approach are clear: It spares healthy cells and lowers drug side effects. It can also extend the life of a under an expiring patent or salvage an antibody that was ineffective by itself. ADCs hold a lot of promise. Of the two approved ADCs, one is soon expected to be a blockbuster. About 30 more are in clinical trials with another 100 or more ADCs in the preclinical pipeline. Projections show that by 2018, sales of ADCs could top $5 billion.

On the manufacturing side, because these drugs are so complex, suppliers are still figuring out how to streamline production. At the moment, ADCs are a niche area of manufacturing with only a few contract manufacturing organizations able to put all the pieces together from start to finish. But many are responding and investing millions to expand capacity for this promising new class.

Explore further: Canines trained on pseudo-explosives could not reliably identify the genuine article

More information: "Building Antibody-Drug Conjugates" cen.acs.org/articles/92/i3/Bui… Drug-Conjugates.html

add to favorites email to friend print save as pdf

Related Stories

Shifting the Internet into high gear

Mar 27, 2013

(Phys.org) —A new-generation analog-to-digital converter (ADC) developed by a joint IBM-EPFL team has the potential to greatly increase the speed and volume of data that can be transferred over the Internet.

Nanomedicines promise fewer side effects in treating cancer

Jun 06, 2012

A new generation of cancer treatments based on nanotechnology is making its way out of the laboratory and into the clinic with the promise of targeting cancer cells while steering clear of healthy tissue, according to the ...

Recommended for you

Molecules that came in handy for first life on Earth

1 hour ago

For the first time, chemists have successfully produced amino acid-like molecules that all have the same 'handedness', from simple building blocks and in a single test tube. Could this be how life started. ...

Jumping hurdles in the RNA world

Nov 21, 2014

Astrobiologists have shown that the formation of RNA from prebiotic reactions may not be as problematic as scientists once thought.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.